Diplomat Pharmacy (DPLO) Releases FY 2019 Earnings Guidance

Share on StockTwits

Diplomat Pharmacy (NYSE:DPLO) issued an update on its FY 2019 earnings guidance on Friday morning. The company provided EPS guidance of $-0.5-0.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.61. The company issued revenue guidance of $4.7-5 billion, compared to the consensus revenue estimate of $5.45 billion.

NYSE DPLO opened at $6.42 on Friday. Diplomat Pharmacy has a 1-year low of $5.56 and a 1-year high of $28.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.95 and a quick ratio of 0.66. The stock has a market capitalization of $485.54 million, a PE ratio of 7.64 and a beta of 0.74.

DPLO has been the subject of a number of recent research reports. Svb Leerink lowered Diplomat Pharmacy from an outperform rating to a market perform rating and lowered their target price for the company from $24.00 to $6.00 in a research note on Monday, February 25th. William Blair lowered Diplomat Pharmacy from a market perform rating to an underperform rating in a research note on Friday, February 22nd. TheStreet lowered Diplomat Pharmacy from a c- rating to a d+ rating in a research note on Monday, March 4th. ValuEngine lowered Diplomat Pharmacy from a sell rating to a strong sell rating in a research note on Monday, February 4th. Finally, Mizuho set a $8.00 target price on Diplomat Pharmacy and gave the company a hold rating in a research note on Friday, February 22nd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $13.78.

COPYRIGHT VIOLATION NOTICE: “Diplomat Pharmacy (DPLO) Releases FY 2019 Earnings Guidance” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4222763/diplomat-pharmacy-dplo-releases-fy-2019-earnings-guidance.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Read More: What Are Treasury Bonds?

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Increases Fidelity National Information Servcs  Price Target to $140.00
Wedbush Increases Fidelity National Information Servcs Price Target to $140.00
ValuEngine Upgrades Lannett  to Hold
ValuEngine Upgrades Lannett to Hold
International Flavors & Fragrances  & Methanex  Head to Head Review
International Flavors & Fragrances & Methanex Head to Head Review
Analyzing Clearway Energy Inc Class C  & Entergy
Analyzing Clearway Energy Inc Class C & Entergy
Darden Restaurants  Given a $130.00 Price Target by Bank of America Analysts
Darden Restaurants Given a $130.00 Price Target by Bank of America Analysts
Commercial Metals  Lifted to Outperform at Macquarie
Commercial Metals Lifted to Outperform at Macquarie


© 2006-2019 Ticker Report